🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPharmacology & MechanismsHas anyone dealt with structure-activity relationships of glp-1 analogs? Page 5

Has anyone dealt with structure-activity relationships of glp-1 analogs?

A1cHero_PHX Sun, Apr 6, 2025 at 7:41 PM 27 replies 1,773 viewsPage 5 of 6
amy_econ_NJ
Member
567
2,567
May 2024
Princeton, NJ
Apr 7, 2025 at 2:46 AM#21

LabKate — that is really helpful context on Has anyone dealt with. Follow-up question: what labs did your doctor order to monitor this?

I am in a similar situation (just started) and trying to set realistic expectations.

45 1Dr.SportsMedIN, amy_econ_NJ, bbq_ray_KC and 42 others
Reply Quote Save Share Report
Dr.DermMIA
Member
456
2,123
May 2024
Miami, FL
Apr 7, 2025 at 3:03 AM#22

To answer matt_MKE's question specifically:

From a clinical standpoint, Has anyone dealt with is an area where we have good evidence.

The short answer: baseline labs + quarterly monitoring is the standard of care.

The longer answer involves understanding the mechanism of action at the receptor level, which I am happy to elaborate on if helpful.

Last edited: Apr 7, 2025 at 5:03 AM
29 18Dr.RenalNash, LipidDoc_ATL, BariatricNurseD and 26 others
Reply Quote Save Share Report
DataDave
Senior Member
1,678
8,901
Apr 2024
Washington
Online
Apr 7, 2025 at 3:20 AM#23

Thank you amy_econ_NJ! This is incredibly helpful. Bookmarking for later. 🙏

34 21LondonLisa, mike_nyc, VendorMark and 31 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides
dan_philly
Member
456
2,123
Jul 2024
Philadelphia, PA
Apr 7, 2025 at 3:37 AM#24

Relevant to Has anyone dealt with — here is my latest bloodwork comparison:

Key improvements: A1C 7.6% → 5.5%, triglycerides 213 → 113 mg/dL, hsCRP 8.0 → 1.3 mg/L. All on tirzepatide for 17 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.

25 22Dr.CardioMD, EndoResFellow, PharmacoVig_BOS and 22 others
Reply Quote Save Share Report
TomFromTexas
Member
645
2,890
May 2024
Austin, TX
Apr 7, 2025 at 3:54 AM#25

Slightly tangential to Has anyone dealt with but amy_econ_NJ reminded me — what is the latest on the oral formulations?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

13 9BiostatsBrad, PeptideSynthNJ, Dr.KarenChen and 10 others
Reply Quote Save Share Report

Similar Threads

GLP-1R desensitization — β-arrestin-mediated internalization18 replies
Biased agonism at GLP-1R — Gs vs β-arrestin signaling balance13 replies
Semaglutide albumin binding and the C-18 fatty acid linker17 replies
GIP receptor pharmacology — why GIP agonism enhances GLP-113 replies
Glucagon receptor signaling — hepatic glycogenolysis and lipolysis16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register